The global Hormone-Sensitive Advanced Prostate Cancer Treatment Market is slated to reach a valuation of USD 12.44 billion in 2023. According to Future Market Insights, the market is expected to grow at a 7.2% CAGR until 2033, reaching a value of USD 24.94 billion.
The primary goal of key providers is to translate science into innovative oncology medicines that help people with cancer globally, where they are committed to bringing new hope, driven by purpose, and supporting accessibility through their cancer medicines.
Recurrent/non-responsive prostate cancer is a major restraint for the growth of the prostate cancer drugs market. This is because recurrent/non-responsive prostate cancer cells lead to the recurrence or spread of cancer after initial treatment.
According to the American Society of Clinical Oncology (ASCO), around 50% to 95% of men in the United States with high-risk prostate cancer experience recurrence after localized treatment.
The prostate cancer drugs market in the United States is regulated by the FDA, which is responsible for the approval of new drugs and lays down regulations related to the treatment of prostate cancer.
This was the first case of FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, and more such approvals are expected to follow in the future. Hence, the regulatory scenario related to prostate cancer drugs will encourage more drug manufacturers to enter the market.
A new treatment is approached for prostate cancer that could stop resistance in its tracks. For the first time, researchers have discovered that prostate cancer can be killed by targeting a single enzyme, called PI5P4Kα.
North America is the largest region in the prostate cancer drugs market in 2022. The Middle East is expected to be the agile growing region in the forecast period. The regions covered in the prostate cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.
| Attributes | Details |
|---|---|
| Projected Forecast Value (2023) | USD 12.44 billion |
| Projected Forecast Value (2033) | USD 24.94 billion |
| Growth rate | 7.2% CAGR |
| Forecast period | 2023 to 2033 |
The global hormone-sensitive advanced prostate cancer treatment market grew at a CAGR of 6.6% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence.
The treatment landscape for patients with hormone-sensitive prostate cancer (HSPC) has changed dramatically in the past five years, despite little change in the preceding 20 years. Such rapid change can make it difficult for clinicians to remain abreast of the current literature and synthesize the relevant data to inform evidence-based treatment decisions.
Although analyses encompassing men with low- and high-volume metastases failed to demonstrate a significant survival benefit for radiotherapy treatment to the prostate, new data demonstrate a benefit for men with low-volume metastatic disease.
Ongoing trials will assess whether this applies to local surgical treatment. Similarly, metastasis-directed therapy appears beneficial among carefully selected patients.
New agents are constantly being developed and evaluated in the HSPC space. As mentioned above, given the advent of more recent changes in therapy for the hormonal-sensitive cancer disease, it notably uses ADT plus docetaxel as the standard of care treatment and examines the addition of darolutamide to this regimen.
Given the favorable results with darolutamide in the castrate-resistant space, this may also have a role within the early HSPC realm.
The increasing male geriatric population
It acts as a major driver for the prostate cancer drugs market. Prostate cancer is one of the most common types of cancer in men aged above 60.
According to ACL (Administration for Community Living), a US-based government organization, the geriatric population is expected to increase by 21.6% by 2040. Among those populations, men are affected more by prostate cancer than women.
For example, in January 2022, according to the American Cancer Society, a US-based organization, prostate cancer develops in older men and non-Hispanic black men, and about 6 cases in 10 are diagnosed in men who are 65 or older (geriatric population). Therefore, the increasing men’s geriatric population drives the prostate cancer market.
Advancements in Cancer Detection Technology
The driving factor for the hormone-sensitive advanced prostate cancer treatment market is the advancement in technologies, personalized medicines, and cost-effective treatment procedures are some of the factors that are expected to provide a boost to the hormone-sensitive advanced prostate cancer treatment market.
Limited Availability of Drugs
Limited commercial availability of drugs and treatments for this cancer is the challenge restraining the growth of the global hormone-sensitive prostate cancer treatment market.
The high cost associated with the treatment will obstruct the growth rate of the market. As per the American Cancer Society, prostate cancer costs on average USD 4,300 upfront and USD 9,100 over five years, with surgery costing USD 15,000 upfront and USD 19,000 over five years.
Hormone therapy with radiation costs USD 17,500 upfront and USD 25,000 over five years. Costs for patients with advanced or metastatic prostate cancer might exceed USD 100,000.
On the other hand, the lack of healthcare infrastructure in developing economies and the dearth of skilled professionals will challenge the hormone-sensitive advanced prostate cancer treatment market. Additionally, lack of awareness among people and unfavorable healthcare policies will act as restraints and further impede the growth rate of the market during the forecast period.
North America accounted for the largest revenue share in the hormone-sensitive advanced prostate cancer treatment market in 2022, and is expected to continue its dominance over the forecast period.
This growth is attributable to a high prevalence of the disease, the presence of regional players, and favorable reimbursement policies. Changing lifestyle is another factor adding to the prevalence of diseases.
The local presence of regulatory entities in North American countries is expected to boost the development of therapies shortly. This is mainly because these entities play a pivotal role in creating awareness among people about the potential of immunotherapy in cancer management.
In Europe, the market for hormone-sensitive advanced prostate cancer treatment is expected to grow at a significant rate during the forecast period due to the combined efforts of several governments & private institutes, such as the European Organization for Research and Treatment of Cancer (EORTC) and the European Medicines Agency (EMA), to develop unique programs focusing on multiple approaches in drug development.
In Asia Pacific, the market for hormone-sensitive advanced prostate cancer treatment is expected to grow at a lucrative rate during the forecast period due to the presence of leading oncology companies and an increase in R&D investments in countries such as China and Japan.
This, in turn, has led to an increase in the development of prostate cancer drugs. Moreover, the cost of clinical trials in developing countries is lesser than that in developed countries.
The demand for hospitals will be more during the forecast period.
According to a report by Future Market Insights, the hospital pharmacies would grow within the anticipated time frame. This market sector is expected to hold a greater share of the worldwide market from 2023 to 2033.
Due to the growing number of people visiting hospitals for advice on treatment related to hormonal cancer, the hospital pharmacy is anticipated to dominate the worldwide hormone-sensitive advanced prostate cancer treatment market.
As a result, individuals more pertain towards their health and well-being. Thus, the majority of consumers are expected to only buy medications from hospital pharmacies.
Androgen ablation therapy is said to hold a dominant share
The goal of this treatment is to reduce levels of male hormones, called androgens, in the body, or to stop them from fueling prostate cancer cell growth.
Androgens stimulate prostate cancer cells to grow. The main androgens in the body are testosterone and dihydrotestosterone (DHT). Most androgens are made by the testicles, but the adrenal glands (glands that sit above your kidneys) as well as the prostate cancer cells themselves, can also make androgens.
Some of the prominent players in the global market for Hormone Sensitive Advanced Prostate Cancer Market treatment are
Some of the important developments of the key players in the market are
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 7.2% from 2023 to 2033 |
| Market value in 2023 | USD 12.44 billion |
| Market value in 2033 | USD 24.94 billion |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | USD billion for Value and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Treatment, End-User, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC countries, South Africa, Israel |
| Key Companies Profiled | Novartis Pharmaceuticals; Merc & Co., Inc.; Bristol-Myers; Dendreon Corporation; GlaxoSmithKline plc.; Ferring International Center S.A.; Roche Group; Celgen Corporation; Amgen Inc.; Teva Pharmaceutical Industries Ltd. |
| Customization Scope | Available on Request |
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 8: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 11: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 12: Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 13: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: South Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 15: South Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 16: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: East Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 18: East Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 19: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 20: Oceania Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 21: Oceania Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 22: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 23: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 24: MEA Market Value (US$ Million) Forecast by End User, 2018 to 2033
Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by End User, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 7: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 8: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 9: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 10: Global Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 11: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 12: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 13: Global Market Attractiveness by Treatment, 2023 to 2033
Figure 14: Global Market Attractiveness by End User, 2023 to 2033
Figure 15: Global Market Attractiveness by Region, 2023 to 2033
Figure 16: North America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 17: North America Market Value (US$ Million) by End User, 2023 to 2033
Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 22: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 23: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 24: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 28: North America Market Attractiveness by Treatment, 2023 to 2033
Figure 29: North America Market Attractiveness by End User, 2023 to 2033
Figure 30: North America Market Attractiveness by Country, 2023 to 2033
Figure 31: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 32: Latin America Market Value (US$ Million) by End User, 2023 to 2033
Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 37: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 40: Latin America Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 41: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 43: Latin America Market Attractiveness by Treatment, 2023 to 2033
Figure 44: Latin America Market Attractiveness by End User, 2023 to 2033
Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 46: Europe Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 47: Europe Market Value (US$ Million) by End User, 2023 to 2033
Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 52: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 53: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 54: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 55: Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 56: Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 57: Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 58: Europe Market Attractiveness by Treatment, 2023 to 2033
Figure 59: Europe Market Attractiveness by End User, 2023 to 2033
Figure 60: Europe Market Attractiveness by Country, 2023 to 2033
Figure 61: South Asia Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 62: South Asia Market Value (US$ Million) by End User, 2023 to 2033
Figure 63: South Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 64: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 65: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 66: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 67: South Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 68: South Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 69: South Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 70: South Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 71: South Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 72: South Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 73: South Asia Market Attractiveness by Treatment, 2023 to 2033
Figure 74: South Asia Market Attractiveness by End User, 2023 to 2033
Figure 75: South Asia Market Attractiveness by Country, 2023 to 2033
Figure 76: East Asia Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 77: East Asia Market Value (US$ Million) by End User, 2023 to 2033
Figure 78: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 79: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 80: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 81: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 82: East Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 83: East Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 84: East Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 85: East Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 86: East Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 87: East Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 88: East Asia Market Attractiveness by Treatment, 2023 to 2033
Figure 89: East Asia Market Attractiveness by End User, 2023 to 2033
Figure 90: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 91: Oceania Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 92: Oceania Market Value (US$ Million) by End User, 2023 to 2033
Figure 93: Oceania Market Value (US$ Million) by Country, 2023 to 2033
Figure 94: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 95: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 96: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 97: Oceania Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 98: Oceania Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 99: Oceania Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 100: Oceania Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 101: Oceania Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 102: Oceania Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 103: Oceania Market Attractiveness by Treatment, 2023 to 2033
Figure 104: Oceania Market Attractiveness by End User, 2023 to 2033
Figure 105: Oceania Market Attractiveness by Country, 2023 to 2033
Figure 106: MEA Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 107: MEA Market Value (US$ Million) by End User, 2023 to 2033
Figure 108: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 109: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 110: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 111: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 112: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 113: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 114: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 115: MEA Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 116: MEA Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 117: MEA Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 118: MEA Market Attractiveness by Treatment, 2023 to 2033
Figure 119: MEA Market Attractiveness by End User, 2023 to 2033
Figure 120: MEA Market Attractiveness by Country, 2023 to 2033
The market to secure a valuation USD 12.44 billion in 2023.
The market is estimated to reach USD 24.94 billion by 2033.
Through 2033, the market is anticipated to expand at a 7.2% CAGR.
From 2018 to 2022, the hormone sensitive advanced prostate cancer treatment market developed at a CAGR of 6.6%.
The market share of hospital pharmacy is projected to rise.
The androgen ablation therapy segment seems to dominate the market.
Explore Therapy Area Insights
Hormone Sensitive Advanced Prostate Cancer Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
